Modern features of the use of anticoagulants in cardiology
https://doi.org/10.21518/2079-701X-2018-5-94-99
Abstract
Thrombosis is one of the leading causes of death and disability around the world, therefore their treatment and prevention are relevant in modern medicine. The article discusses the features and possible applications of the new oral anticoagulants in General, and particularly of apixaban as the newest representative of this group of drugs.
About the Author
N. V. Dobryninа
Ryazan State Medical University named after academician I.P. Pavlov
Russian Federation
Russian Federation
PhD
References
1. Bokarev I. Death every 37 seconds. [Electronic resource]. GAZETA. RU. 28.08.2012. URL: https://www.gazeta.ru/ science/2012/08/28_a_4739733.shtml (accessed date April 22, 2017).
2. Eliseeva LN, Blednova AYu, Denisova NN, et al. Apixaban: from guidelines to everyday practice. Meditsinskiy Sovet, 2016, 9: 6-10.
3. Reiffel JA. Atrial fibrillation and stroke: epidemiology. Am J Med, 2014, 127: 15-16.
4. Lagoda OV. Antithrombotic therapy in patients with cardioembolic ischemic stroke. Nevrologiya i Revmatologiya, 2016, 1: 33-36.
5. Ashikhmin YaI, Schekochikhin DYu. Individualized antithrombotic therapy for atrial fibrillation. Farmateka, 2013, 18: 119-123.
6. Pereverzeva KG, Pravkina EA, Nikulina NN, Vorobiev AN. Analysis of anti-thrombotic therapy in atrial fibrillation in outpatient practice in Ryazan as part of a registry study of cardiovascular diseases. In the book: Kalinin RE, ed. Healthcare: education, science, innovations: materials of the All-Russian Scientific and Practical Conference with international participation dedicated to the 70th anniversary of the Pavlov Ryazan State Medical University. Ryazan, 2013: 333-335.
7. Sacco RL, Adams R, Albers G et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. Stroke, 2006, 37: 577-617.
8. Dobrinina NV. What we know about candesartan: potential of clinical administration. Consilium Medicum, 2016, 5: 67-69.
9. Heidbuchel H, Verhamme P, Alings M et al. Updated European Heart Rhythm Association Practical Guide on the use of non- vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace, 2015, 17(10):1467-1507.
10. Kamm JA. Anticoagulation therapy in atrial fibrillation: current issues and future strategy. Cardiology, 2014, 2: 14-25. 11.2012 focused update ESC Guidelines for the management of atrial fibrillation. Eur. Heart J, 2012, 33: 2719-2747.
11. Khorev NG, Momot AP, Zalozny DA. New oral anticoagulants (literature review). Farmateka, 2010, 18/19: 20-26.
12. Hart RGM, Pearse LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med, 2007, 146: 857-867.
13. Connolly S, Pogue G, Hart R еt al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet, 2006, 367: 1903-1912.
14. Kobalava ZhD, Villevalde SV, Troitskaya EA. The problem of adherence to anticoagulant therapy and ways to its solution. Kardiologiya, 2016, 56: 71-78.
15. Dolgova EL, Sokolov IM, Shvarts YuG. How to choose appropriate anticoagulant for the prevention of stroke in patients with atrial fibrillation. Meditsinskiy Sovet, 2014, 12: 58-62.
16. Angelli G, Buller H, Curto M et al. Oral Apixaban for the Treatment of Acute Venous Thromboembolism. N. Engl. J. Med, 2013, 369(9): 799-808.
17. Connoly SJ, Eikelboom J, Joyner C. on behalf of AVERROUS Steering Committee and Investigators. Apixaban in Patient with Atrial Fibrillation. N. Engl. J. Med, 2011, 364(9): 2093-2104.
18. Grander C, Alexander J, McMurrey J et al. Apixaban versus warfarin in patient with atrial fibrillation. N. Engl. J. Med, 2011, 365: 981-992.
19. Pereverzeva KG, Vorobyov AN, Martsevich SY, Lukyanov MM, Moseychuk KA. Analysis of the management of patients with coronary heart disease and atrial fibrillation in real outpatient practice. Nauka Molodykh - Eruditio Juvenium, 2015, 1: 48-55.
20. Pereverzeva KG, Vorobiev AN, Nikulina NN, Moseichuk KA, Pravkina EA, Yakushin SS. Features of the examination of patients with ischemic heart disease in outpatient practice according to observation in a registry study. Rossiyskiy Mediko-biologicheskiy Vestnik Im. Akademika I.P. Pavlova, 2014, 1: 90-96.
21. Barbarash OL, Kashtalap VV. Approaches to rational antithrombotic therapy in patients with acute coronary syndrome and non-valvular atrial fibrillation (based on the materials of the European Congress of Cardiology in 2014). Consilium Medicum, 2015, 5: 49-53.
22. Napalkov DA, Sokolova AA. Anticoagulant therapy with direct oral anticoagulants beyond clinical guidelines: a complex choice of a clinician and a personal-ized approach to treatment. Farmateka, 2016, 13: 87-90.
23. Petrov VS. The results of a 5-year follow-up of patients with rheumatic heart disease. Rossiyskiy Mediko-biologicheskiy Vestnik Im. Akademika I.P. Pavlova, 2015, 3: 83-87.
24. Vrijens B, Heidbuchel H. Non – vitamin K antagonist anticoagulants: considerations on once – vs. twice – daily regimens and their potential impact on medication adherence. Europase, 2015, 17(4): 514-523.
25. Renda G, De Katerina R. The new anticoagulants in atrial fibrillation: once daily or twice – daily? Vascul. Pharmacol, 2013, 59(3-4): 53-62.
Review
For citations:
Dobryninа NV. Modern features of the use of anticoagulants in cardiology. Meditsinskiy sovet = Medical Council. 2018;(5):94-99. (In Russ.) https://doi.org/10.21518/2079-701X-2018-5-94-99
Views:
636
Email this article 